264 related articles for article (PubMed ID: 36927273)
1. An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
J Psychopharmacol; 2023 Apr; 37(4):381-395. PubMed ID: 36927273
[TBL] [Abstract][Full Text] [Related]
2. CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
Psychopharmacology (Berl); 2020 Dec; 237(12):3665-3687. PubMed ID: 32851421
[TBL] [Abstract][Full Text] [Related]
3. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
[TBL] [Abstract][Full Text] [Related]
4. Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
Int J Psychophysiol; 2019 Nov; 145():70-82. PubMed ID: 30790597
[TBL] [Abstract][Full Text] [Related]
5. The acute dose and baseline amplitude-dependent effects of CDP-choline on deviance detection (MMN) in chronic schizophrenia: A pilot study.
Aidelbaum R; Labelle A; Choueiry J; Knott V
Exp Clin Psychopharmacol; 2022 Apr; 30(2):235-248. PubMed ID: 33630646
[TBL] [Abstract][Full Text] [Related]
6. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Rosse RB; Mastropaolo J; Gaskins B
Clin Neuropharmacol; 2008; 31(1):34-9. PubMed ID: 18303489
[TBL] [Abstract][Full Text] [Related]
7. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
[TBL] [Abstract][Full Text] [Related]
8. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
Deutsch SI; Rosse RB; Schwartz BL; Schooler NR; Gaskins BL; Long KD; Mastropaolo J
Eur Neuropsychopharmacol; 2008 Feb; 18(2):147-51. PubMed ID: 17656074
[TBL] [Abstract][Full Text] [Related]
9. CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression.
Knott V; Smith D; de la Salle S; Impey D; Choueiry J; Beaudry E; Smith M; Saghir S; Ilivitsky V; Labelle A
J Psychopharmacol; 2014 Dec; 28(12):1095-108. PubMed ID: 25315828
[TBL] [Abstract][Full Text] [Related]
10. Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: A pilot study.
Aidelbaum R; Labelle A; Baddeley A; Knott V
J Psychopharmacol; 2018 May; 32(5):541-551. PubMed ID: 29338621
[TBL] [Abstract][Full Text] [Related]
11. Acute separate and combined effects of cannabinoid and nicotinic receptor agonists on MMN-indexed auditory deviance detection in healthy humans.
de la Salle S; Inyang L; Impey D; Smith D; Choueiry J; Nelson R; Heera J; Baddeley A; Ilivitsky V; Knott V
Pharmacol Biochem Behav; 2019 Sep; 184():172739. PubMed ID: 31283908
[TBL] [Abstract][Full Text] [Related]
12. Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers.
Knott V; Salle S; Smith D; Choueiry J; Impey D; Smith M; Beaudry E; Saghir S; Ilivitsky V; Labelle A
Neurosci Lett; 2015 Mar; 591():121-125. PubMed ID: 25700947
[TBL] [Abstract][Full Text] [Related]
13. Modulation of auditory deviance detection by acute nicotine is baseline and deviant dependent in healthy nonsmokers: a mismatch negativity study.
Knott V; Impey D; Philippe T; Smith D; Choueiry J; de la Salle S; Dort H
Hum Psychopharmacol; 2014 Sep; 29(5):446-58. PubMed ID: 25196041
[TBL] [Abstract][Full Text] [Related]
14. Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers.
Knott V; de la Salle S; Choueiry J; Impey D; Smith D; Smith M; Beaudry E; Saghir S; Ilivitsky V; Labelle A
Pharmacol Biochem Behav; 2015 Apr; 131():119-29. PubMed ID: 25681529
[TBL] [Abstract][Full Text] [Related]
15. CDP-choline attenuates scopolamine induced disruption of prepulse inhibition in rats: involvement of central nicotinic mechanism.
Uslu G; Savci V; Buyukuysal LR; Goktalay G
Neurosci Lett; 2014 May; 569():153-7. PubMed ID: 24708927
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
Beinat C; Banister SD; Herrera M; Law V; Kassiou M
CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
[TBL] [Abstract][Full Text] [Related]
17. Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine in healthy human subjects.
Hahn B; Shrieves ME; Olmstead CK; Yuille MB; Chiappelli JJ; Pereira EFR; Albuquerque EX; Fawcett WP
Psychopharmacology (Berl); 2020 Jan; 237(1):219-230. PubMed ID: 31686175
[TBL] [Abstract][Full Text] [Related]
18. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
Kelly DL; McMahon RP; Weiner E; Boggs DL; Dickinson D; Conley RR; Buchanan RW
Schizophr Res; 2008 Aug; 103(1-3):161-8. PubMed ID: 18550339
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of JWX-A0108 as a novel type I positive allosteric modulator of α7 nAChR that can reverse acoustic gating deficits in a mouse prepulse inhibition model.
Sun LL; Yang TY; Wei NN; Lu W; Jiao WX; Zhou QQ; Miao YZ; Gao Q; Wang XT; Sun Q; Wang K
Acta Pharmacol Sin; 2019 Jun; 40(6):737-745. PubMed ID: 30333556
[TBL] [Abstract][Full Text] [Related]
20. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.
Hamilton HK; D'Souza DC; Ford JM; Roach BJ; Kort NS; Ahn KH; Bhakta S; Ranganathan M; Mathalon DH
Schizophr Res; 2018 Jan; 191():87-94. PubMed ID: 28711472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
